$51.18
▲ +4.0% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says
Wedbush Raises Price Target on Hemab Therapeutics to $55 From $42, Keeps Outperform Rating
Overview
52-week range
$23
$37
100% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
-0.6%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 21, 2026 | Mar/2026 | $-23.98 | — | — | — | -0.6% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-16.18 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 20, 2026 | Jun/2026 | OTHER | -$0.63 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-24M | — | $-17M |
| Net income | $-23M | — | $-15M |
| EPS (diluted) | $-23.98 | — | $-16.18 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $50M | $88M | — |
| Inventory | — | — | — |
| Total current assets | $169M | $193M | — |
| Total assets | $175M | $195M | — |
| Long-term debt | — | — | — |
| Total liabilities | $14M | $11M | — |
| Total equity | $-199M | $-177M | — |
Implied volatility — last 90 days
No IV snapshots yet for COAG.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.